This is a phase II, randomized, double-blind, placebo-controlled, multi-center study to
evaluate the safety, tolerability, and efficacy of adrenocorticotropic hormone (ACTH, Acthar
gel) administered as a pulsed regimen consisting of injections on three consecutive days per
month in patients with progressive forms of Multiple Sclerosis (MS). Patients will be
randomly assigned to either an ACTH arm or a placebo arm. The main hypotheses are that 1)
pulsed ACTH will be safe and well-tolerated, and 2) pulsed ACTH will slow progression of
clinical and paraclinical measures of MS progression compared to placebo.
Phase:
Phase 2
Details
Lead Sponsor:
University of Minnesota University of Minnesota - Clinical and Translational Science Institute